Vitiligo

Vitiligo is a chronic autoimmune depigmenting disorder characterized by the selective destruction of melanocytes, leading to well-defined white macules and patches on the skin. Although medically benign, vitiligo carries profound psychosocial implications, particularly when lesions affect visible areas such as the face and hands. As a major pigmentary focus at every international Dermatology Conference, this session explores evolving understanding of immune-mediated melanocyte loss and the expanding landscape of targeted therapies. Closely associated with autoimmune depigmentation disorders, vitiligo management integrates immunology, regenerative strategies, and long-term monitoring.

The session begins with an exploration of pathogenesis, highlighting cytotoxic T-cell–mediated melanocyte destruction and oxidative stress imbalance. Genetic susceptibility and environmental triggers such as trauma or sunburn may initiate or accelerate depigmentation. Participants will review segmental and non-segmental subtypes, as well as stable versus progressive disease classification.

Clinical diagnosis is typically straightforward, supported by Wood’s lamp examination to enhance lesion contrast. Differential diagnosis includes post-inflammatory hypopigmentation, tinea versicolor, and chemical leukoderma. Early identification is essential, as active inflammation may respond more effectively to treatment.

Therapeutic options have evolved significantly. Topical corticosteroids and calcineurin inhibitors remain foundational in localized disease, while narrowband UVB phototherapy supports repigmentation in widespread cases. Recent advances include JAK inhibitors targeting inflammatory signaling pathways implicated in melanocyte destruction.

Surgical techniques such as melanocyte transplantation may be considered in stable vitiligo. Regenerative approaches aim to stimulate residual melanocytes and promote pigment spread from hair follicles. Camouflage strategies and cosmetic counseling also play important supportive roles.

Psychological care is emphasized throughout, as visible depigmentation may affect self-esteem and social interaction. Patient education regarding chronicity and realistic expectations improves adherence and satisfaction.

Emerging research into immune modulation and stem cell activation continues to refine vitiligo therapy. By integrating immunologic precision with compassionate care, dermatologists can improve both repigmentation outcomes and quality of life for affected individuals.